Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.87 USD | -5.48% | -5.32% | -13.55% |
May. 07 | ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 07 | Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, vs. Street Est of $7M | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.55% | 161M | - | ||
+10.03% | 223B | B | ||
+13.59% | 195B | B- | ||
+20.01% | 144B | B- | ||
+30.83% | 111B | A- | ||
+2.05% | 65.01B | A- | ||
+15.38% | 53.02B | B+ | ||
+3.96% | 50.45B | B+ | ||
+8.37% | 44.15B | A | ||
+3.27% | 36.45B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CLPT Stock
- Ratings ClearPoint Neuro, Inc.